W
William W. Hope
Researcher at University of Liverpool
Publications - 276
Citations - 20739
William W. Hope is an academic researcher from University of Liverpool. The author has contributed to research in topics: Population & Pharmacodynamics. The author has an hindex of 59, co-authored 249 publications receiving 17604 citations. Previous affiliations of William W. Hope include Princess Alexandra Hospital & HealthPartners.
Papers
More filters
Journal ArticleDOI
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben E. De Pauw,Thomas J. Walsh,J. Peter Donnelly,David A. Stevens,John E. Edwards,Thierry Calandra,Peter G. Pappas,Johan Maertens,Olivier Lortholary,Carol A. Kauffman,David W. Denning,Thomas F. Patterson,Georg Maschmeyer,Jacques Bille,William E. Dismukes,Raoul Herbrecht,William W. Hope,Christopher C. Kibbler,Bart Jan Kullberg,Kieren A. Marr,Patricia Muñoz,Frank C. Odds,John R. Perfect,Angela Restrepo,Markus Ruhnke,Brahm H. Segal,Jack D. Sobel,Tania C. Sorrell,Claudio Viscoli,John R. Wingard,Theoklis E. Zaoutis,John E. Bennett +31 more
TL;DR: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
Journal ArticleDOI
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
Oliver A. Cornely,Matteo Bassetti,Thierry Calandra,Jorge Garbino,Bart Jan Kullberg,O. Lortholary,O. Lortholary,Wouter Meersseman,Murat Akova,Maiken Cavling Arendrup,S. Arikan-Akdagli,Jacques Bille,Elio Castagnola,Manuel Cuenca-Estrella,J.P. Donnelly,Andreas H. Groll,Raoul Herbrecht,William W. Hope,Henrik Jeldtoft Jensen,Cornelia Lass-Flörl,George Petrikkos,Malcolm Richardson,Emmanuel Roilides,Paul E. Verweij,Claudio Viscoli,Andrew J. Ullmann +25 more
TL;DR: This part of the EFISG guidelines focuses on non-neutropenic adult patients, and liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength for the targeted initial treatment of candidaemia.
Journal ArticleDOI
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Oliver A. Cornely,S. Arikan-Akdagli,Eric Dannaoui,Andreas H. Groll,Katrien Lagrou,Arunaloke Chakrabarti,Fanny Lanternier,Fanny Lanternier,Livio Pagano,Anna Skiada,Murat Akova,Maiken Cavling Arendrup,Teun Boekhout,Teun Boekhout,Anuradha Chowdhary,Manuel Cuenca-Estrella,Tomáš Freiberger,Jesús Guinea,Josep Guarro,S. de Hoog,William W. Hope,Elizabeth M. Johnson,Shallu Kathuria,Michaela Lackner,Cornelia Lass-Flörl,O. Lortholary,Jacques F. Meis,Joseph Meletiadis,Patricia Muñoz,Malcolm Richardson,Emmanuel Roilides,Anna Maria Tortorano,Andrew J. Ullmann,A.D. van Diepeningen,Paul E. Verweij,George Petrikkos +35 more
TL;DR: These European Society for Clinical Microbiology and Infectious Diseases and European Confederation of Medical Mycology Joint Clinical Guidelines focus on the diagnosis and management of mucormycosis and strongly recommend continuing treatment until complete response demonstrated on imaging and permanent reversal of predisposing factors.
Journal ArticleDOI
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
Jason A. Roberts,Jason A. Roberts,Mohd H. Abdul-Aziz,Jeffrey Lipman,Jeffrey Lipman,Johan W. Mouton,Alexander A. Vinks,Timothy Felton,William W. Hope,Andras Farkas,Michael Neely,Jerome J. Schentag,George L. Drusano,Otto R Frey,Ursula Theuretzbacher,Joseph L. Kuti +15 more
TL;DR: The challenges related to patients and pathogens that contribute to inadequate antibiotic dosing are explored and how to implement a process for individualised antibiotic therapy that increases the accuracy of dosing and optimises care for critically ill patients is discussed.
Journal ArticleDOI
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan Maertens,Issam I Raad,Kieren A. Marr,Thomas F. Patterson,Dimitrios P. Kontoyiannis,Oliver A. Cornely,Eric J. Bow,Galia Rahav,Dionysios Neofytos,Mickael Aoun,John W. Baddley,Michael Giladi,Werner J. Heinz,Raoul Herbrecht,William W. Hope,Meinolf Karthaus,Dong-Gun Lee,Olivier Lortholary,Vicki A. Morrison,Ilana Oren,Dominik Selleslag,Shmuel Shoham,George Richard Thompson,Misun Lee,Rochelle Maher,Anne Schmitt-Hoffmann,Bernhardt Zeiher,Andrew J. Ullmann +27 more
TL;DR: The results support the use of isavuconazole for the primary treatment of patients with invasive mould disease and non-inferiority was shown.